List of Excipients in Branded Drug QVAR REDIHALER

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
A-S Medication Solutions	QVAR REDIHALER	beclomethasone dipropionate hfa	50090-3458	ALCOHOL
A-S Medication Solutions	QVAR REDIHALER	beclomethasone dipropionate hfa	50090-3458	NORFLURANE
A-S Medication Solutions	QVAR REDIHALER	beclomethasone dipropionate hfa	50090-3459	ALCOHOL
A-S Medication Solutions	QVAR REDIHALER	beclomethasone dipropionate hfa	50090-3459	NORFLURANE
A-S Medication Solutions	QVAR REDIHALER	beclomethasone dipropionate hfa	50090-5031	ALCOHOL

QVAR RediHaler Excipient Strategy, Patent Position, and Commercial Opportunities

Last updated: October 29, 2026

QVAR RediHaler is a breath-actuated inhaled corticosteroid product containing beclomethasone dipropionate. Its commercial differentiation comes primarily from the inhaler platform and formulation simplicity rather than a complex excipient system. The product uses hydrofluoroalkane-134a, or HFA-134a, as the propellant and ethanol as the cosolvent. It does not require shaking before use and is designed for patients who have difficulty coordinating inhaler actuation with inhalation.[1]

The main commercial opportunities are reformulation, device-compatible excipient development, pediatric and adherence-focused products, regional licensing, and follow-on inhaled corticosteroid combinations. The main risks are device patent barriers, FDA requirements for in vitro equivalence and therapeutic equivalence, limited excipient differentiation, and competition from other inhaled corticosteroids and combination inhalers.

What excipients are used in QVAR RediHaler?

QVAR RediHaler contains beclomethasone dipropionate, HFA-134a propellant, and ethanol.[1]

Component	Function	Commercial relevance
Beclomethasone dipropionate	Active corticosteroid	Anti-inflammatory treatment for asthma
HFA-134a	Propellant and dispersion medium	Controls aerosol generation and delivered dose
Ethanol	Cosolvent	Supports drug solubilization and formulation stability
Device components	Metering and breath-actuation system	Controls actuation, aerosolization, and dose delivery

QVAR RediHaler is a solution aerosol rather than a conventional chlorofluorocarbon-based suspension inhaler. The formulation uses ethanol to help dissolve beclomethasone dipropionate in the HFA vehicle. This approach reduces the need for surfactants or complex suspension-stabilizing systems.

The absence of a large excipient package has two implications. First, the formulation may be easier to scale than a multi-excipient dry powder or suspension product. Second, formulation-based differentiation is narrower because most of the product’s performance is tied to the valve, actuator, inhaler airflow path, and breath-actuation mechanism.

How does QVAR RediHaler’s excipient strategy work?

The formulation strategy is based on a low-excipient HFA solution system.

HFA-134a as the propellant

HFA-134a provides the pressure required to aerosolize the formulation. It replaced ozone-depleting chlorofluorocarbon propellants in many metered-dose inhalers. Its role extends beyond simple propulsion. Propellant vapor pressure, density, solvent behavior, and interaction with the metering valve affect:

• Droplet size distribution
• Fine-particle dose
• Plume geometry
• Valve reproducibility
• Canister residual volume
• Deposition in the inhaler and respiratory tract

HFA-134a remains commercially established, but sustainability pressure is increasing. The European Union, United Kingdom, and other markets are encouraging lower-global-warming-potential propellants. That creates a potential reformulation path using HFA-152a or hydrofluoroolefin-based propellants, subject to safety, device, manufacturing, and regulatory validation.

Ethanol as a cosolvent

Ethanol improves the solubility of beclomethasone dipropionate in the HFA formulation. Its concentration influences aerosol performance and can affect:

• Drug solubility
• Evaporation rate
• Droplet shrinkage
• Delivered dose uniformity
• Valve and elastomer compatibility
• Taste and throat sensation
• Chemical stability

Ethanol is also a potential optimization variable for follow-on products. Changes in ethanol concentration can alter aerodynamic particle-size distribution and regional lung deposition. A formulation that matches the reference product’s emitted dose but changes fine-particle fraction may face additional FDA scrutiny.

Why QVAR RediHaler does not use a broad excipient platform

QVAR RediHaler does not depend on lactose carriers, phospholipids, suspending agents, or complex particle-engineering excipients. This distinguishes it from dry powder inhalers and some suspension metered-dose inhalers.

The commercial advantage is manufacturing simplicity. The limitation is that a competitor cannot easily create a differentiated product by changing only a conventional excipient. Meaningful differentiation generally requires one or more of the following:

1. A new propellant.
2. A new cosolvent ratio.
3. A redesigned valve or actuator.
4. A modified breath-actuation system.
5. A different particle-size or aerosol-performance profile.
6. A combination product using an additional active ingredient.

What is QVAR RediHaler’s FDA regulatory status?

QVAR RediHaler is FDA-approved for the maintenance treatment of asthma in patients age four years and older. It is not indicated for relief of acute bronchospasm.[1]

Regulatory item	Status
Active ingredient	Beclomethasone dipropionate
Dosage form	Inhalation aerosol
Strengths	40 mcg and 80 mcg per actuation
FDA product type	New drug application product
Indication	Maintenance treatment of asthma
Pediatric use	Patients age four years and older
Rescue use	Not indicated
Device	Breath-actuated inhaler
Spacer requirement	Not required under labeled use
Shaking	Not required before use under the product labeling

The product was approved under NDA 208911 in 2017, according to FDA approval materials and product labeling.[1,2] QVAR RediHaler was developed as a successor to the earlier QVAR metered-dose inhaler and uses a breath-actuated platform intended to reduce actuation-inhalation coordination errors.

What commercial advantages does the QVAR RediHaler excipient system provide?

The formulation provides four commercial advantages.

Lower excipient complexity

The use of HFA-134a and ethanol limits raw-material complexity. A relatively simple solution formulation may reduce risks associated with particle suspension, sedimentation, redispersion, and dose stratification.

Device-driven differentiation

QVAR RediHaler can compete on ease of use rather than solely on pharmacology. Breath actuation is commercially relevant because incorrect coordination is common with conventional pressurized metered-dose inhalers.

Potential for manufacturing scale

HFA solution products can use established canister filling and metering-valve infrastructure. The major manufacturing controls remain formulation homogeneity, valve crimping, fill weight, leak testing, delivered-dose uniformity, and aerodynamic performance.

Pediatric positioning

The product is approved for children age four years and older. A breath-actuated system may offer an alternative to conventional metered-dose inhalers that require coordinated actuation and inhalation. Pediatric opportunities include lower-dose optimization, improved mouthpiece ergonomics, dose counters, and adherence-monitoring systems.

What formulation patents protect QVAR RediHaler?

QVAR RediHaler protection is likely to depend more heavily on the inhaler device, breath-actuation system, metering mechanism, and drug-device combination than on the basic use of HFA-134a and ethanol.

Public FDA labeling identifies the product and its formulation but does not provide a complete patent landscape.[1] A definitive patent analysis requires current review of the FDA Orange Book, USPTO records, Patent Center, international family data, and litigation dockets. Patent scope may include:

• Breath-actuated inhaler architecture
• Actuation thresholds
• Airflow-triggered valve release
• Dose metering
• Actuator geometry
• Canister-valve integration
• Inhaler lockout mechanisms
• Use of beclomethasone dipropionate in the device
• Formulation stability and aerosol performance
• Manufacturing methods

The key strategic point is that an ANDA sponsor may avoid a narrow formulation claim while still encountering device or drug-device combination claims. An applicant seeking a generic or authorized generic product therefore must evaluate the entire product architecture, not only the excipient composition.

When does QVAR RediHaler lose exclusivity?

QVAR RediHaler’s regulatory exclusivity and patent exclusivity are separate.

FDA marketing exclusivity depends on the NDA approval pathway and applicable statutory provisions. Patent exclusivity depends on issued claims, patent term adjustments, patent term extensions, terminal disclaimers, and Orange Book listing status.

Exclusivity category	Relevance to QVAR RediHaler
New chemical entity exclusivity	Generally not the principal protection because beclomethasone was previously marketed
NDA-related exclusivity	May apply depending on the approval basis and listed exclusivity periods
Pediatric exclusivity	Could add six months if granted for qualifying FDA-requested studies
Formulation patents	May protect the HFA solution or stability profile
Device patents	May protect breath actuation, valves, metering, and airflow systems
Method-of-use patents	Could cover asthma maintenance treatment or patient populations
Regulatory data protection	Depends on the FDA approval and exclusivity history

No single public date should be treated as the definitive generic-entry date without reconciling Orange Book listings, patent term calculations, and litigation outcomes. Generic applicants may file Paragraph IV certifications before patent expiration and can litigate listed patents while FDA approval remains subject to applicable statutory stays.

What Paragraph IV challenges and generic entry risks exist?

A generic applicant seeking approval for an inhaled product must demonstrate pharmaceutical equivalence and bioequivalence under FDA requirements for orally inhaled drug products. For complex inhalation products, this may include comparative data on:

• Delivered dose
• Dose uniformity
• Aerodynamic particle-size distribution
• Fine-particle dose
• Spray pattern or plume geometry
• Single-actuation content
• Priming and repriming
• Stability
• Device performance
• Human-factor considerations where relevant

A Paragraph IV certification could challenge patents listed in the Orange Book. Generic-entry risks fall into three categories.

Formulation substitution risk

A competitor may use a different ethanol concentration, a different propellant, or a different solution composition. The applicant must show that the formulation delivers an equivalent product despite excipient differences.

Device substitution risk

A competitor may design around the breath-actuated mechanism while maintaining the same active ingredient and strength. This can reduce direct infringement risk but may increase FDA development costs because the device behavior must be validated independently.

Authorized generic risk

Teva or another rights holder could launch an authorized generic using the same or substantially similar formulation and device, subject to applicable commercial arrangements. An authorized generic can reduce the price gap available to a Paragraph IV entrant.

Which companies are challenging QVAR RediHaler?

The competitive field includes manufacturers of inhaled corticosteroids, combination inhalers, and generic or follow-on inhalation products. Relevant competitors include products containing:

• Fluticasone propionate
• Budesonide
• Mometasone furoate
• Ciclesonide
• Fluticasone furoate
• Beclomethasone dipropionate

Specific Paragraph IV challengers, settlement parties, and litigation status must be verified against current FDA Orange Book entries and federal court dockets. Public product competition is broader than direct QVAR RediHaler substitution because physicians may select a different inhaled corticosteroid or an inhaled corticosteroid/long-acting beta agonist combination.

What licensing deals could create opportunities around QVAR RediHaler?

The most attractive licensing opportunities are likely to involve technology rather than the basic excipient package.

Lower-global-warming-potential propellants

A licensor with HFA-152a or hydrofluoroolefin expertise could partner with an inhaler manufacturer to develop a lower-emissions beclomethasone product. The development package would need to address formulation solubility, pressure, flammability, valve compatibility, extractables, device manufacturing, and lifecycle stability.

Breath-actuated inhaler platforms

Device companies could license actuation mechanisms to generic manufacturers. Platform licensing may support a QVAR-equivalent product without copying protected device claims.

Smart inhaler systems

Electronic dose tracking, adherence monitoring, Bluetooth connectivity, and caregiver alerts could support premium products, especially in pediatric asthma and managed-care channels.

Regional commercialization

Companies with established respiratory sales infrastructure in Latin America, the Middle East, Southeast Asia, or selected European markets may seek rights to a beclomethasone HFA product. Regional value depends on patent status, local device registration, reimbursement, and availability of competing inhaled corticosteroids.

How strong is the QVAR RediHaler patent estate?

The estate is potentially stronger at the product-system level than at the excipient level.

Protection layer	Relative strategic value
HFA-134a alone	Low, because the propellant is widely used
Ethanol as cosolvent	Low to moderate unless tied to a specific concentration or performance result
Beclomethasone HFA solution	Moderate, depending on claim breadth and prior art
Aerosol performance profile	Moderate to high if claim limitations are specific and reproducible
Breath-actuated device	High if claims cover core actuation and metering functions
Drug-device combination	Moderate to high, depending on claim construction
Manufacturing process	Moderate if process claims provide practical production barriers
Method of use	Variable, with value dependent on claim scope and remaining patient population

The strongest barriers are likely to be claims that connect formulation composition with measurable aerosol performance or claims covering the essential breath-actuated mechanism. Broad claims to HFA-134a, ethanol, or beclomethasone alone would face substantial prior-art pressure.

What manufacturing and intellectual-property barriers affect follow-on products?

A follow-on QVAR-type product must overcome several practical barriers.

Valve and actuator reproducibility

Small changes in valve dimensions, elastomer composition, or crimping can affect emitted dose and plume characteristics. A product may meet chemical specifications while failing aerodynamic equivalence.

Device human factors

A breath-actuated product must respond reliably to different inhalation profiles. Pediatric and elderly users may produce lower inspiratory flows, creating a risk of under-actuation or inconsistent dosing.

Extractables and leachables

HFA, ethanol, elastomers, plastics, coatings, and adhesives can interact over the product shelf life. Extractables and leachables testing is central to regulatory acceptance.

Stability

Stability testing must account for drug degradation, valve performance, canister pressure, ethanol loss, container closure integrity, and changes in particle-size distribution.

Proprietary manufacturing knowledge

Even when patent claims expire, process know-how can remain commercially relevant. Examples include filling conditions, valve insertion, crimp specifications, actuator tolerances, and in-process aerosol testing.

How does QVAR RediHaler compare with competing inhaled corticosteroids?

Product category	Main differentiation	Excipient and device implications
QVAR RediHaler	Beclomethasone, breath actuation	HFA-134a and ethanol solution
Fluticasone HFA products	High-prescription-volume inhaled corticosteroid	HFA formulation and conventional or dose-counter devices
Budesonide DPI products	Dry powder delivery	Lactose carrier and inspiratory-flow dependence
Mometasone DPI products	Dry powder inhaled corticosteroid	Carrier-based powder engineering
ICS/LABA combinations	Dual pharmacology	More complex formulation, device, and regulatory requirements

QVAR RediHaler’s primary advantage is ease of use. Its commercial disadvantage is that it competes against established inhaled corticosteroids and combination products with stronger formulary positions or broader clinical use.

What revenue exposure is associated with QVAR RediHaler?

Teva does not generally disclose QVAR RediHaler revenue as a standalone audited segment in its principal public financial reporting. Revenue exposure must therefore be assessed using prescription volume, net price, payer mix, market share, and channel data rather than a separately reported product figure.[3]

The commercial exposure includes:

• Direct QVAR RediHaler sales
• Cannibalization of older QVAR products
• Reimbursement changes
• Generic or authorized-generic price erosion
• Substitution by inhaled corticosteroid combinations
• Pediatric and primary-care prescribing
• Government and managed-care formulary decisions

A successful generic launch could cause rapid price erosion if multiple manufacturers enter. A device-protected product may experience a slower transition if substitution is limited by device differences, prescriber preference, or the need for a distinct regulatory pathway.

What are the highest-value commercial opportunities?

The strongest opportunities are:

1. Developing a lower-global-warming-propellant version.
2. Creating a generic or follow-on product with a noninfringing breath-actuated device.
3. Licensing a smart inhaler platform.
4. Expanding pediatric adherence solutions.
5. Developing beclomethasone combinations with a long-acting bronchodilator.
6. Commercializing regional rights where QVAR-style HFA products have limited competition.
7. Supplying specialized valves, actuators, or low-extractables components.
8. Offering contract development and manufacturing services for HFA solution inhalers.

The most defensible opportunities combine formulation expertise with device engineering. Excipient substitution alone is less likely to create a durable moat.

Key Takeaways

• QVAR RediHaler uses beclomethasone dipropionate, HFA-134a, and ethanol.
• Its excipient system is comparatively simple and is designed as an HFA solution aerosol.
• Commercial differentiation comes mainly from the breath-actuated inhaler rather than a complex excipient platform.
• The most relevant intellectual-property risks involve the device, valve, actuation system, drug-device combination, and aerosol-performance claims.
• Generic developers must address delivered dose, aerodynamic particle size, device performance, and human-factor requirements.
• Lower-global-warming propellants are the clearest long-term reformulation opportunity.
• Product-level QVAR RediHaler revenue is not separately disclosed in Teva’s principal public reporting.
• A successful follow-on product will need both regulatory equivalence and a practical strategy for avoiding device-related patent claims.

FAQs

Is ethanol necessary in QVAR RediHaler?

Ethanol functions as a cosolvent and supports dissolution of beclomethasone dipropionate in the HFA formulation. Removing or materially changing it could alter solubility, aerosol performance, stability, and delivered dose.

Can QVAR RediHaler be reformulated with HFA-152a?

Potentially, but the change would require new formulation and device development. Key issues include pressure, flammability, solubility, valve compatibility, extractables, stability, manufacturing controls, and FDA comparability requirements.

Does QVAR RediHaler require lactose?

No. QVAR RediHaler is an HFA aerosol solution and does not use lactose as a dry-powder carrier.

Is a generic QVAR RediHaler required to copy the Teva device?

Not necessarily. A generic applicant may pursue a different device, but it must satisfy FDA requirements for the proposed product and avoid applicable device, formulation, and drug-device combination patents.

What is the main commercial weakness of QVAR RediHaler?

The principal weakness is limited formulation differentiation against other inhaled corticosteroids and combination inhalers. Its commercial value depends heavily on device usability, formulary access, price, and the ability to maintain protection against generic or follow-on substitution.

References

1. U.S. Food and Drug Administration. (2024). QVAR RediHaler: Prescribing information. Teva Respiratory, LLC.

2. U.S. Food and Drug Administration. (2017). Drugs@FDA: QVAR RediHaler, NDA 208911. Center for Drug Evaluation and Research.

3. Teva Pharmaceutical Industries Ltd. (2024). Annual report and Form 20-F. Teva Pharmaceutical Industries Ltd.